This is a medication used to treat certain types of breast cancer. It works by blocking the effects of estrogen in the body, which helps stop the cancer cells from growing. It's often used for breast cancer that has spread to other parts of the body.
Every report comes from a Lived member, sent anonymously.
Have you tried Faslodex (Fulvestrant) for Breast Cancer?
Fulvestrant, sold under the brand name Faslodex and also available as generic injections, is a hormone therapy for advanced breast cancer that is hormone receptor-positive (HR-positive). That means the cancer cells carry receptors for estrogen or progesterone and use these hormones as a growth signal. "Advanced" here means cancer that has spread to other parts of the body (metastatic) or has grown into nearby tissue in a way surgery cannot simply remove. Fulvestrant is not used for early-stage breast cancer after surgery. On its own, fulvestrant is approved for postmenopausal women with HR-positive advanced breast cancer, either as a first hormone treatment or after the cancer has grown despite another hormone therapy such as tamoxifen or an aromatase inhibitor. It is more often given together with a daily pill. The most common partners are CDK4/6 inhibitors, targeted drugs that slow cancer cell division: palbociclib (Ibrance), abemaciclib (Verzenio) and ribociclib (Kisqali). These combinations are for cancers that are also HER2-negative, meaning they do not overproduce the HER2 growth protein. When tumor testing finds changes in specific genes (PIK3CA, AKT1 or PTEN), fulvestrant may instead be paired with a pill that targets that pathway, such as capivasertib (Truqap), alpelisib (Piqray), or inavolisib (Itovebi) together with palbociclib. Women who have not gone through menopause can receive fulvestrant combinations too, but they also need treatment that switches off estrogen production by the ovaries with a medicine called an LHRH (luteinizing hormone-releasing hormone) agonist.
Estrogen fuels the growth of HR-positive breast cancer by attaching to estrogen receptors inside the cancer cells, which signals the cells to grow and divide. Fulvestrant attaches to the same receptors with about the same strength as the body's own estrogen and blocks estrogen from using them. It also causes the cells to break the receptor down, so there are fewer receptors left to respond. Because of this, it is sometimes called a selective estrogen receptor degrader, or SERD. This differs from aromatase inhibitors such as anastrozole, which lower how much estrogen the body makes. In laboratory studies, fulvestrant also slowed breast cancer cells that had become resistant to tamoxifen, which is part of why it is used after other hormone therapies stop working. Pairing it with a targeted pill attacks a second growth pathway at the same time, which is the idea behind the combination treatments.
Fulvestrant is given at a cancer clinic or infusion center as an injection into the muscle of the buttocks, not under the skin and not as a pill. The usual dose is 500 mg, given as two injections at the same visit, one in each buttock. Each injection is given slowly, over one to two minutes. The first month has an extra loading dose: injections on day 1, day 15 and day 29, then once a month after that. People with moderate liver impairment receive half the dose (one injection) on the same schedule; it has not been studied in severe liver disease. When fulvestrant is combined with a targeted pill, the pill is taken at home on its own schedule, which may include a week off each month, and that drug's dosing and blood tests are managed separately.
The most common complaint is pain or soreness at the injection sites. Other frequent side effects include nausea, tiredness, headache, hot flashes, bone, joint and back pain, loss of appetite and constipation. Blood tests often show mildly raised liver enzymes, which the care team tracks. When fulvestrant is combined with a targeted pill, most of the stronger side effects, such as low blood counts, diarrhea or high blood sugar, come from the partner drug. Because the injection goes deep into the buttock near the sciatic nerve, nerve irritation has occasionally been reported. Pain, numbness or tingling that runs down the leg after an injection should be reported to the care team. Allergic reactions are uncommon, but swelling of the face, lips, tongue or throat, or trouble breathing after an injection, needs emergency help by calling 911.
Fulvestrant has no known significant interactions with other medicines. Because it is injected into muscle, it can cause bleeding or bruising at the injection site in people who take blood thinners such as warfarin or apixaban, or who have a bleeding disorder or low platelet counts. The care team should know about these before the first dose. Fulvestrant can harm a developing baby. Anyone who could become pregnant should use effective birth control during treatment and for one year after the last injection, and should tell the care team right away about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for one year after the last dose. Fulvestrant can make some estradiol (estrogen) blood tests read falsely high. This matters for women whose menopause status is being checked with blood tests, so the lab and care team should know about the treatment.
Treatment usually continues for as long as the cancer stays under control and side effects remain manageable, which may be many months or years. Response is checked with periodic scans, physical exams, symptom review and blood tests. If scans show the cancer is growing, the oncologist will usually switch to a different treatment rather than increase the dose. The benefit is measured in how long the cancer is held in check. In the trial that led to its approval as a first hormone treatment, postmenopausal women given fulvestrant alone went a median of about 16.6 months before their cancer progressed, compared with 13.8 months on the aromatase inhibitor anastrozole. Fulvestrant controls advanced breast cancer rather than curing it, and how long it works differs widely from person to person. After the first month the schedule settles into one clinic visit a month. Most of the routine is built around that visit, the injection soreness that can follow it, and the scans and blood tests in between.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Faslodex (Fulvestrant), what you've noticed, or ask the community a question.